• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J.Infect.Dis. Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluen

tetano

Editor, Senior Moderator
[h=1]Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012?2013 and 2013?2014[/h] David K. Shay
Yoganand Chillarige
Jeffrey Kelman
Richard A. Forshee
Ivo M. Foppa
Michael Wernecke
Yun Lu
Jill M. Ferdinands
Arjun Iyengar
Alicia M. Fry
... Show more


J Infect Dis jiw641.
DOI:
https://doi.org/10.1093/infdis/jiw641


Published:
02 March 2017

Article history


[h=2]Abstract[/h] Background.
Recipients of high-dose vs standard-dose influenza vaccines have fewer influenza illnesses. We evaluated the comparative effectiveness of high-dose vaccine in preventing postinfluenza deaths during 2012?2013 and 2013?2014, when influenza viruses and vaccines were similar.
Methods.
We identified Medicare beneficiaries aged ≥65 years who received high-dose or standard-dose vaccines in community-located pharmacies offering both vaccines. The primary outcome was death in the 30 days following an inpatient or emergency department encounter listing an influenza International of Classification of Diseases, Ninth Revision, Clinical Modification code. Effectiveness was estimated by using multivariate Poisson regression models; effectiveness was allowed to vary by season.
Results.
We studied 1039645 recipients of high-dose and 1683264 recipients of standard-dose vaccines during 2012?2013, and 1508176 high-dose and 1877327 standard-dose recipients during 2013?2014. Vaccinees were well-balanced for medical conditions and indicators of frail health. Rates of postinfluenza death were 0.028 and 0.038/10000 person-weeks in high-dose and standard-dose recipients, respectively. Comparative effectiveness was 24.0% (95% confidence interval [CI], .6%?42%); there was evidence of variation by season (P = .12). In 2012?2013, high-dose was 36.4% (95% CI, 9.0%?56%) more effective in reducing mortality; in 2013?2014, it was 2.5% (95% CI, ?47% to 35%).
Conclusions.
High-dose vaccine was significantly more effective in preventing postinfluenza deaths in 2012?2013, when A(H3N2) circulation was common, but not in 2013?2014.



full article

https://academic.oup.com/jid/articl...Comparative-Effectiveness-of-High-Dose-Versus
 
Back
Top